Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 21,200 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Phase 1 Interventional

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

NCT04578600
View directory record Official record
Conditions
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Obinutuzumab, Oral Azacitidine
Drug · Biological
Lead sponsor
Joseph Tuscano
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 23, 2026, 4:21 AM EDT
Terminated Not applicable Interventional Results available

Intravesical BCG Administration to Patients With Invasive Bladder Cancer

NCT02365207
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG strain of Mycobacterium bovis
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

NCT02345707
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Cabotegravir 30 mg current formulation, Cabotegravir 30 mg micronized new formulation 500 M, Cabotegravir 30 mg unmicronized new formulation 500 U, Cabotegravir 30 mg micronized new formulation 650 M, Cabotegravir 30 mg unmicronized new formulation 650 U
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

NCT01829711
View directory record Official record
Conditions
Leukemia, Hairy Cell
Interventions
Moxetumomab pasudotox, IV Bag Protectant for Moxetumomab pasudotox
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 4 Interventional

Effect of Age and Device on Delivery of Fluticasone

NCT00308932
View directory record Official record
Conditions
Asthma
Interventions
HFA FP MDI
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 23, 2026, 4:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acne Vulgaris Related Microbiology and Serology

NCT04056598
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Study of humoral immunity
Diagnostic Test
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

NCT00131677
View directory record Official record
Conditions
HIV Infection
Interventions
tenofovir disoproxil fumarate, placebo
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 60 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Study of the Efficacy and Safety of Maintenance Treatment With Oral Ganciclovir for Newly Diagnosed Cytomegalovirus Retinitis in People With AIDS

NCT00002257
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Berkeley, California • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 4:21 AM EDT
Completed No phase listed Observational

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

NCT05349201
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL)
Interventions
KYMRIAH, YESCARTA
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

NCT00217412
View directory record Official record
Conditions
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
vorinostat, isotretinoin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 23, 2026, 4:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

NCT04797767
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm, Relapsed Acute Biphenotypic Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Mixed Phenotype Acute Leukemia, Relapsed Myeloid Neoplasm, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myeloid Neoplasm, Recurrent Myeloid Sarcoma
Interventions
Cladribine, Cytarabine, Mitoxantrone, Recombinant Granulocyte Colony-Stimulating Factor, Venetoclax, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 4:21 AM EDT
Active, not recruiting Not applicable Interventional

AIDANET Pediatrics

NCT07020936
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Normal Glycemia Goal, Tight Glycemia Goal
Device
Lead sponsor
Mark D. DeBoer, MD, MSc., MCR
Other
Eligibility
6 Years to 13 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 23, 2026, 4:21 AM EDT
Active, not recruiting Not applicable Interventional

The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV

NCT07466836
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Chiropractic Care
Procedure
Lead sponsor
Tyson Perez, DC, PhD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Shared Medical Appointments to Improve Outcomes in Adolescents With Type 1 Diabetes

NCT02547311
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Team Clinic
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
11 Years to 17 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

NCT01545232
View directory record Official record
Conditions
Trauma
Interventions
1:1:1 Blood Transfusion Ratio, 1:1:2 Blood Transfusion Ratio
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
15 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Insomnia Prevention in Children With Acute Lymphoblastic Leukemia

NCT05866887
View directory record Official record
Conditions
Pediatric Acute Lymphoblastic Leukemia, Leukemia, Acute Lymphoblastic Leukemia
Interventions
Sleep ALL Night
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 23, 2026, 4:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

NCT00113919
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Busulfan
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 23, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

NCT02031419
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
CC-122, CC-223, Rituximab, CC-292
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
8
States / cities
Stanford, California • New Haven, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

NCT00537030
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Interventions
Asparaginase, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 23, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

NCT00660530
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Disease
Interventions
Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 23, 2026, 4:21 AM EDT
Terminated No phase listed Observational

Connect® MM- The Multiple Myeloma Disease Registry

NCT01081028
View directory record Official record
Conditions
Multiple Myeloma
Interventions
First-line therapy, Second-line Multiple Myeloma treatments
Other · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
3,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
252
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 4:21 AM EDT
Not listed Not applicable Interventional

Effect of a Community-based Nursing Intervention on Mortality in Chronically Ill Older Adults

NCT01071967
View directory record Official record
Conditions
Heart Failure, Coronary Disease, Diabetes Mellitus, Asthma, Hypertension, Hypercholesterolemia
Interventions
Community-based nurse care management
Other
Lead sponsor
Health Quality Partners
Other
Eligibility
65 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Doylestown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Oct 23, 2026, 4:21 AM EDT
Completed No phase listed Observational

Evaluation of Albuminuria HIV-Infected Patients

NCT00524992
View directory record Official record
Conditions
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 23, 2026, 4:21 AM EDT